DUXAP8 and hepatocellular carcinoma: Mechanistic experiments demonstrated that DUXAP8 mitigated the susceptibility of HCC cell to sorafenib-mediated ferroptosis by reducing the membrane translocation of SLC7A11, promoting its lysosomal sorting and hindering its degradation in lysosomes, which actually activated the SLC7A11 action [128].